Continuous Heparin Infusion to Prevent Catheter-related Thrombosis

Sponsor
Guangdong Provincial People's Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04767113
Collaborator
(none)
124
1
2
12
10.4

Study Details

Study Description

Brief Summary

Catheter-related thrombosis could impair blood flow in the vein, block the central venous catheter, induce catheter-related infection or venous thromboembolism in the deep veins or pulmonary vessels, which furthermore progress into the post-thrombotic syndrome.

Researches using echogenic mass as the primary outcome could miss those premature thrombi which might not be seen on traditional ultrasonography but may be detected by Duplex and Doppler ultrasound with vessel compression. Moreover, studies indicated that some thrombus developed after the catheter removal. Removal of the catheter is not the endpoint of thrombus detection. This study is designed to determine the preventive effects of continuous heparin infusion on real-world central venous catheter-related thrombosis in infants after cardiac surgery.

Condition or Disease Intervention/Treatment Phase
  • Drug: Heparin sodium
  • Drug: Normal saline
N/A

Detailed Description

Catheter-related thrombosis could impair blood flow in the vein, block the central venous catheter, induce catheter-related infection or venous thromboembolism in the deep veins or pulmonary vessels, which furthermore progress into the post-thrombotic syndrome. Researches using echogenic mass as the primary outcome could miss those premature thrombi which might not be seen on traditional ultrasonography but may be detected by Duplex and Doppler ultrasound with vessel compression. Moreover, studies indicated that some thrombus developed after the catheter removal. Removal of the catheter is not the endpoint of thrombus detection. This study is designed to determine the preventive effects of continuous heparin infusion on real-world central venous catheter-related thrombosis in infants after cardiac surgery. One hundred and twenty-four infants were randomized to the intervention group or the control group. Unfractionated heparin or normal saline was infused continuously through each lumen of the central venous catheter at the speed of 0.5 ml/h/line until the catheter was removed. Catheter-related thrombosis was detected by point-of-care Duplex and Doppler ultrasound periodically until 30 days after the cardiac surgery or discharge, whichever comes first.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
124 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Infant participants were blinded naturally, while ultrasonographers for central venous catheter (CVC)-related thrombosis were blinded, especially after interventions were stopped.
Primary Purpose:
Prevention
Official Title:
A Randomized, Controlled Trial of Continuous Heparin Versus Placebo Infusion to Prevent Catheter-related Thrombosis in Infants After Cardiac Surgery
Anticipated Study Start Date :
Mar 1, 2021
Anticipated Primary Completion Date :
Feb 28, 2022
Anticipated Study Completion Date :
Feb 28, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Heparin group

Continuous infusion of heparin was used to maintain the patency of CVC.

Drug: Heparin sodium
For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h. For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol.
Other Names:
  • unfractionated heparin
  • Placebo Comparator: Control group

    Continuous infusion of heparin was used at the corresponding speed.

    Drug: Normal saline
    For infants enrolled, normal saline was infused at the corresponding speed.

    Outcome Measures

    Primary Outcome Measures

    1. 124 infants of CVC-related thrombosis by point-of-care echography or ultrasound [30 days after cardiac surgery or at discharge, whichever comes first]

      CVC-related thrombosis of any catheter as imaged by echocardiogram or ultrasound at 30 days after cardiac surgery. Thrombus was defined as an echogenic mass near the tip of the catheter or slow/no flow detected by Duplex and Doppler ultrasound at the nearby vessels and the on-site vessel couldn't be clasped as narrow as the collateral vessel by compression of the probe.

    Secondary Outcome Measures

    1. 124 infants of heparin-related comorbidity [30 days after cardiac surgery or at discharge, whichever comes first]

      Abnormal coagulation and hemostasis were defined as treatment initiation by the clinical teams at the discretion of heparin adverse events. Heparin-induced thrombocytopenia was confirmed with consistent low platelet level and positive enzyme-linked immunosorbent assay heparin-platelet factor 4 antibody assay. Catheter-related sepsis was defined as culture of the same organism from both the catheter tip and at least one percutaneous blood culture. Culture of the same organism from the catheter was also accepted as an alternative of culture of catheter tip.

    Other Outcome Measures

    1. Post-thrombotic syndrome [6 months after cardiac surgery]

      The symptoms of post-thrombotic syndrome included aching, swelling, itchy and ulcer in the indwelling site and the collateral varicose veins.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 3 Months
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • less than 3 months of age at admission, post-cardiac surgery, with CVC indwelled
    Exclusion Criteria:
    • parents' refusal, requiring postoperative anticoagulant administration (extracorporeal membrane oxygenation support, prosthetic devices), the contradiction to heparin (coagulopathy or hypercoagulable state, platelet level less than 50000/dL, clinically significant bleeding tendency, allergy to heparin)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Guangdong Provincial People's Hospital Guangzhou Guangdong China 510080

    Sponsors and Collaborators

    • Guangdong Provincial People's Hospital

    Investigators

    • Principal Investigator: Yunxia Sun, MD, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Guangdong Provincial People's Hospital
    ClinicalTrials.gov Identifier:
    NCT04767113
    Other Study ID Numbers:
    • GPPH heparin for thrombosis
    First Posted:
    Feb 23, 2021
    Last Update Posted:
    Feb 23, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 23, 2021